BRIUMVI

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug BRIUMVI contains one active pharmaceutical ingredient (API):

1	Ublituximab UNII U59UGK3IPC - UBLITUXIMAB
	Ublituximab is a chimeric monoclonal antibody that selectively targets CD20-expressing cells. CD20 is a cell surface antigen found on pre-B cells, mature and memory B cells but not expressed on lymphoid stem cells and plasma cells. The binding of ublituximab to CD20 induces lysis of CD20+ B cells.
	Read more about Ublituximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRIUMVI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG14		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3036710
FR	Base de données publique des médicaments	61216870
IT	Agenzia del Farmaco	050698012
LT	Valstybinė vaistų kontrolės tarnyba	1097211
US	FDA, National Drug Code	73150-150